Honda Motor Co would reduce car production at two plants in Suzuka by up to 40 percent in early October due to ongoing supply chain and logistical problems.
The carmaker would also cut production at its assembly plant in Saitama prefecture by about 30 percent for the period.
For the rest of September, Honda would reduce vehicle production at Saitama by about 40 percent and at Suzuka by about 20 percent.
There is a persistent shortage of chips and supply chain disruptions in the first half of the business year.
Honda attributed logistics and COVID-19 outbreaks as the cause of parts delivery delays. A number of vehicles, including the Vezel sport utility vehicle, Stepwgn minivan, and Civic compact car, will experience the output cut.
After a previous drop, Honda's production at those two factories returned to normal in June, but the firm indicated previously that it started making changes once more the following month.


European Stocks Steady as U.S.-Iran War, Euro Zone Data Keep Investors Cautious
Synlait Milk Denies Fonterra, a2 Milk Takeover Talks
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump
Oil Prices Fall as U.S. Crude Inventories Surge and Hormuz Tensions Persist
S&P 500 Hits Record High as Soft Inflation Data Eases Fed Rate Hike Fears
Malaysia Inflation Eases to 1.8% in July, Below Forecast
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories
Barclays Warns U.S. Stock Rally May Be Detached From Fundamentals
Gold Prices Rise as Weak US Data and Hormuz Risks Boost Safe-Haven Demand
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth
US Dollar Slips as Weak Retail Sales Reduce Fed Rate Hike Bets
Trump Imposes New US Tariffs on Drone Imports Over National Security Concerns
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised
Strait of Hormuz Shipping Near Standstill After New Vessel Attacks
Trump Imposes New Tariffs on Drone Imports Over US Security Concerns
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case 



